1. Al-imidazole
2. Cu-imidazole
3. Imidazole Acetate
4. Imidazole Citrate
5. Imidazole Conjugate Monoacid
6. Imidazole Monohydrochloride
7. Imidazole Monophosphonate
8. Imidazole Sodium
9. Imidazolium Chloride
1. 1h-imidazole
2. 288-32-4
3. Glyoxaline
4. Imidazol
5. Iminazole
6. Miazole
7. 1,3-diazole
8. Glyoxalin
9. Imutex
10. 1,3-diaza-2,4-cyclopentadiene
11. Pyrro(b)monazole
12. Usaf Ek-4733
13. Pyrro[b]monazole
14. Formamidine, N,n'-vinylene-
15. Glioksal [polish]
16. Glioksal
17. Imd
18. Methanimidamide, N,n'-1,2-ethenediyl-
19. Ccris 3345
20. Ai3-24703
21. Nsc 60522
22. Brn 0103853
23. 1h-imidazole, Dimer
24. N,n'-vinyleneformamidine
25. Chembl540
26. 7gbn705nh1
27. Dtxsid2029616
28. Chebi:16069
29. N,n'-1,2-ethenediylmethanimidamide
30. Mfcd00005183
31. Nsc-60522
32. Dsstox_cid_9616
33. Dsstox_rid_78788
34. Dsstox_gsid_29616
35. 227760-40-9
36. 1h-imidazol
37. Cas-288-32-4
38. Imidazole (8ci)
39. Nsc51860
40. Imidazole, Puriss. P.a., >=99.5% (gc)
41. Einecs 206-019-2
42. Nsc 51860
43. Unii-7gbn705nh1
44. Immidazole
45. Imidazole-
46. 1-h-imidazole
47. Glyoxaline Solution
48. Imidazole, Reagent
49. {pyrro[b]monazole}
50. 1,4-cyclopentadiene
51. Imidazole, Acs Grade
52. 1h-imidazole (9ci)
53. Imidazole [mi]
54. Imidazole [inci]
55. Imidazole Buffer Solution
56. Formamidine,n'-vinylene-
57. Bmse000096
58. Bmse000790
59. Wln: T5m Cnj
60. Ec 206-019-2
61. Enalapril Impurity I
62. Imidazole [usp-rs]
63. Imidazole [who-dd]
64. Ncistruc1_001975
65. Ncistruc2_000693
66. Imidazole, Lr, >=99%
67. 5-23-04-00191 (beilstein Handbook Reference)
68. Mls001055465
69. Bdbm7882
70. Imidazole-buffered Saline (5x)
71. Imidazole-[2-13c,15n2]
72. Hsdb 8449
73. 1,3-diaza-2,4-cyclopentadiene-
74. Imidazole, Reagentplus(r), 99%
75. Zinc901039
76. Imidazole, For Synthesis, 99.5%
77. Bcp26547
78. Hy-d0837
79. Nsc60522
80. Methanimidamide,n'-1,2-ethenediyl-
81. Tox21_201504
82. Tox21_303345
83. S6006
84. Stk362967
85. Akos000120177
86. Am82000
87. Cs-5135
88. Db03366
89. Imidazole, Bioultra, >=99.5% (gc)
90. Ncgc00090984-01
91. Ncgc00090984-02
92. Ncgc00257344-01
93. Ncgc00259055-01
94. 2,4-diazonia-2,4-cyclopentadiene-1-ide
95. Bp-11451
96. Him
97. Smr000057825
98. 1,3-diaza-2,4-cyclopentadiene;glyoxaline
99. Imidazole, Saj Special Grade, >=99.0%
100. Imidazole, Vetec(tm) Reagent Grade, 98%
101. Db-002018
102. Imidazole, 0.5m Buffer Solution, Ph 6.0
103. Imidazole, 0.5m Buffer Solution, Ph 7.0
104. Imidazole, 0.5m Buffer Solution, Ph 7.5
105. Clotrimazole Impurity D [ep Impurity]
106. Ft-0627179
107. Ft-0670295
108. I0001
109. I0014
110. I0288
111. I0290
112. Imidazole, >=99% (titration), Crystalline
113. Imidazole Zone Refined (number Of Passes:30)
114. Imidazole, Acs Reagent, >=99% (titration)
115. C01589
116. P17516
117. Enalapril Maleate Impurity I [ep Impurity]
118. Imidazole Buffer Solution, Bioultra, 1 M In H2o
119. Q328692
120. J-200340
121. Sildenafil Citrate Impurity E [ep Impurity]
122. Imidazole, For Molecular Biology, >=99% (titration)
123. F2190-0638
124. Z1245636370
125. Imidazole, Bioultra, For Molecular Biology, >=99.5% (gc)
126. Imidazole, European Pharmacopoeia (ep) Reference Standard
127. 4286d518-643c-4c69-bce7-519d073f4992
128. Imidazole, Pharmaceutical Impurity Standard, >=95.0% (hplc)
129. Imidazole, United States Pharmacopeia (usp) Reference Standard
130. Imidazole;1,3-diazole; Glyoxaline; 1,3-diazacyclopenta-2,4-diene
131. Ondansetron Hydrochloride Dihydrate Impurity E [ep Impurity]
132. Ondansetron Hydrochloride Impurity, Imidazole- [usp Impurity]
133. Imidazole, Anhydrous, Free-flowing, Redi-dri(tm), Acs Reagent, >=99%
134. Imidazole, Pharmaceutical Secondary Standard; Certified Reference Material
135. Ondansetron Impurity E, European Pharmacopoeia (ep) Reference Standard
| Molecular Weight | 68.08 g/mol |
|---|---|
| Molecular Formula | C3H4N2 |
| XLogP3 | -0.1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 0 |
| Exact Mass | 68.037448136 g/mol |
| Monoisotopic Mass | 68.037448136 g/mol |
| Topological Polar Surface Area | 28.7 Ų |
| Heavy Atom Count | 5 |
| Formal Charge | 0 |
| Complexity | 28.1 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
Imidazole reached peak plasma levels within 15 to 30 minutes in rats dosed with approximately 17 mg/kg bw and disappeared within 4 hours. Similar results were obtained for imidazole with ITF 182, a novel drug called Selezen that consists of the salt of protonated imidazole and 2-hydroxybenzoate in 1:1 molar quantities, with doses containing up to 66 mg imidazole/kg bw. The pharmacokinetic parameters were determined in human studies with ITF 182 in single (248 mg of imidazole) and multiple dose (3 single doses per day) studies. The pharmacokinetic parameters were comparable between different experiments, i.e. single or multiple dosing, oral or rectal applications, or oral tablet or oral drops did not exert marked influences. The main pharmacokinetic parameters in humans after oral intake may be summarized as follows: maximum plasma levels were reached after approximately 3 hours, elimination half-life was approximately 1.8 to 3 hours. Bioavailability was complete. Protein binding was determined to range between 5 to 15 %. In contrast, no effects were noted in a pilot study after dermal application.
OECD; Screening Information Data Set (SIDS) Inital Assessment Report for SIDS Initial Assessment Meeting (SIAM) 17 Imidazole (CAS 288-32-4) p.11 (August 2005). Available from, as of July 30, 2018: https://www.inchem.org/pages/sids.html
Response of enzymes involved in liver drug metabolism to imidazole treatment was determined in several studies. No increase in total microsomal P450 content was observed after a 4 day i.p. administration of 200 mg/kg bw per day in female Sprague-Dawley rats. Statistically significantly increased activities of 7-ethoxycoumarin-O-deethylase (1.7-fold) and Aminopyrine-N-demethylase (1.26-fold) were noted whereas aniline and p-nitrophenol hydroxylases were insignificantly reduced. New Zealand White rabbits treated with imidazole (200 mg/kg bw, 4 days) showed increased total p450-content in liver (1.24-fold) compared with controls and a 4.47-fold increase of the isozyme 3a. No significant changes were noted in pretreated Syrian Hamsters of both sexes (200 mg/kg bw, 4 days) with respect to relative liver weight, total microsomal p450-content, microsomal and cytosolic enzyme activities involved in phase I (demethylation of p-nitroanisole and ethylmorphine, NADPH-Cytochrome C-reductase) and phase II drug metabolism (sulfotransferase, glutathione transferase).
OECD; Screening Information Data Set (SIDS) Inital Assessment Report for SIDS Initial Assessment Meeting (SIAM) 17 Imidazole (CAS 288-32-4) p.11 (August 2005). Available from, as of July 30, 2018: https://www.inchem.org/pages/sids.html
... Elimination half-life /in humans/ was approximately 1.8 to 3 hours.
OECD; Screening Information Data Set (SIDS) Inital Assessment Report for SIDS Initial Assessment Meeting (SIAM) 17 Imidazole (CAS 288-32-4) p.11 (August 2005). Available from, as of July 30, 2018: https://www.inchem.org/pages/sids.html
LOOKING FOR A SUPPLIER?
